No Data
No Data
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 Loss per Share (Vs US$3.63 Profit in 2Q 2023)
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Pieris Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.
Shareholder Alert: Ademi LLP Investigates Whether Pieris Pharmaceuticals, Inc. Has Obtained a Fair Price for Its Public Shareholders
Trending Stocks Today | Nuzee Surges 273.78%